Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)
Provided By GlobeNewswire
Last update: May 24, 2025
– Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world setting –
Read more at globenewswire.com38.56
+0.06 (+0.16%)
Find more stocks in the Stock Screener
MLYS Latest News and Analysis
